KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBITDA Margin: 2011-2025

Historic EBITDA Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -31.35%.

  • Supernus Pharmaceuticals' EBITDA Margin fell 5460.00% to -31.35% in Q3 2025 from the same period last year, while for Sep 2025 it was -5.42%, marking a year-over-year decrease of 1451.00%. This contributed to the annual value of 12.34% for FY2024, which is 1321.00% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' EBITDA Margin is -31.35%, which was down 527.27% from 7.34% recorded in Q2 2025.
  • Supernus Pharmaceuticals' EBITDA Margin's 5-year high stood at 24.14% during Q2 2021, with a 5-year trough of -31.35% in Q3 2025.
  • Over the past 3 years, Supernus Pharmaceuticals' median EBITDA Margin value was 3.37% (recorded in 2023), while the average stood at 1.00%.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' EBITDA Margin soared by 2,638bps in 2024, and later slumped by 5,460bps in 2025.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' EBITDA Margin stood at 3.83% in 2021, then soared by 1,668bps to 20.52% in 2022, then plummeted by 2,113bps to -0.61% in 2023, then soared by 1,290bps to 12.29% in 2024, then tumbled by 5,460bps to -31.35% in 2025.
  • Its EBITDA Margin stands at -31.35% for Q3 2025, versus 7.34% for Q2 2025 and -6.85% for Q1 2025.